KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Non Operating Income (2016 - 2025)

Novavax has reported Non Operating Income over the past 12 years, most recently at $9.5 million for Q4 2025.

  • Quarterly results put Non Operating Income at $9.5 million for Q4 2025, down 27.7% from a year ago — trailing twelve months through Dec 2025 was $40.6 million (changed 0.47% YoY), and the annual figure for FY2025 was $40.6 million, changed 0.47%.
  • Non Operating Income for Q4 2025 was $9.5 million at Novavax, up from $9.2 million in the prior quarter.
  • Over the last five years, Non Operating Income for NVAX hit a ceiling of $64.0 million in Q4 2022 and a floor of -$34.8 million in Q3 2022.
  • Median Non Operating Income over the past 5 years was $6.6 million (2023), compared with a mean of $6.2 million.
  • Peak annual rise in Non Operating Income hit 14639.86% in 2022, while the deepest fall reached 756.31% in 2022.
  • Novavax's Non Operating Income stood at $434000.0 in 2021, then soared by 14639.86% to $64.0 million in 2022, then tumbled by 82.83% to $11.0 million in 2023, then grew by 19.58% to $13.1 million in 2024, then decreased by 27.7% to $9.5 million in 2025.
  • The last three reported values for Non Operating Income were $9.5 million (Q4 2025), $9.2 million (Q3 2025), and $11.9 million (Q2 2025) per Business Quant data.